Last 13 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.83 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 37.81 | 13.30 | 6.99 | 53.33 | 652.84 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1094.6% | -120.1% | -123.2% | -544.1% | -5732.5% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -280.4% | -71.4% | -62.3% | -79.2% | -79.6% | -173.2% | -130.3% | -158.0% | -201.8% | -246.1% | -0.3% | -0.5% | — |
| — | +58.8% | +52.2% | +49.9% | +60.6% | +29.6% | -51390.4% | -31415.0% | — | -33883.4% | — | — | — | |
| ROIC | — | -152.2% | -455.6% | — | — | — | — | — | — | — | — | — | -0.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 26.5% YoY to 0.56x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.20 | 0.56 | 1.03 | 1.16 | 1.20 | 0.76 | 0.05 | 0.04 | 0.03 | 0.07 | 0.13 | 0.08 | — |
| — | -26.5% | +2078.2% | +2841.5% | +3640.9% | +1011.1% | -63.3% | -51.3% | — | -23.3% | — | — | — | |
| Quick Ratio | 1.20 | 0.56 | 1.03 | 1.16 | 1.20 | 0.76 | 0.05 | 0.04 | 0.03 | 0.07 | 0.13 | 0.08 | — |
| — | -26.5% | +2078.2% | +2841.5% | +3640.9% | +1011.1% | -63.3% | -51.3% | — | -23.3% | — | — | — | |
| Interest Coverage | -3.32 | — | — | — | -392.59 | -5.57 | -1.00 | -0.76 | -3.76 | -0.46 | -1.31 | -2.14 | -1.88 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonOS Therapies Incorporated's current P/E is -2.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking OS Therapies Incorporated's business trajectory between earnings reports.